Brief: Gritstone Bio Announces Positive Preliminary Data

Gritstone bio

01/04/2024 21:10

April 1 (Reuters) - Gritstone bio Inc  GRTS.O :
    * GRITSTONE BIO ANNOUNCES POSITIVE PRELIMINARY
PROGRESSION-FREE
SURVIVAL AND LONG-TERM CIRCULATING TUMOR DNA (CTDNA) DATA FROM
PHASE 2 PORTION OF ONGOING PHASE 2/3 STUDY OF ITS PERSONALIZED
CANCER VACCINE, GRANITE, IN FRONT-LINE METASTATIC MICROSATELLITE
STABLE COLORECTAL CANCER (MSS-CRC)
    * GRITSTONE BIO INC: MATURE PFS DATA EXPECTED IN Q3 OF 2024;
OVERALL SURVIVAL DATA EXPECTED IN 1H 2025
    * GRITSTONE BIO INC: GRANITE WAS GENERALLY WELL-TOLERATED
WITH
MANAGEABLE ADVERSE EVENTS

Source text for Eikon:  ID:nGNX4xRz3d 
Further company coverage:  GRTS.O 

 ((Reuters.Briefs@thomsonreuters.com;))